AbbVie, Astellas Pharma, and AstraZeneca announced partnerships for the Linzess drug's sales and development in various markets.

The entities involved

• AbbVie →

  pharmaceutical company

  • AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Sun 10:21
  • MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Sat 22:36
• Astellas Pharma →

  company

  • Novo Nordisk and Astellas Pharma are noted as large-cap healthcare companies, with Novo Nordisk reporting higher revenue and earnings.Fri 18:20
• AstraZeneca →

  British-Swedish pharmaceutical company

  • AstraZeneca presented trial results at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.Sun 20:11
  • AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.Sat 16:57

Related events

• Astellas Pharma, a Japan-based pharmaceutical company, was noted.Oct 12
• A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Jun 24
• AbbVie and Eli Lilly are competing in the pharmaceutical market.Jun 18
• Eli Lilly and AstraZeneca are involved in drug development and market competition, with the FDA issuing approvals and legal actions involving both companies.Oct 7
• Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.Oct 8